MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 328918 | Name: Esomeprazole Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Esomeprazole Sodium, also known as Nexium and H-199, is the S-isomer of omeprazole and acts as a proton pump inhibitor gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.

Chemical Structure

Esomeprazole Sodium
Esomeprazole Sodium
CAS#161796-78-7 (sodium)

Theoretical Analysis

MedKoo Cat#: 328918

Name: Esomeprazole Sodium

CAS#: 161796-78-7 (sodium)

Chemical Formula: C17H18N3NaO3S

Exact Mass: 0.0000

Molecular Weight: 367.40

Elemental Analysis: C, 55.58; H, 4.94; N, 11.44; Na, 6.26; O, 13.06; S, 8.73

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
161796-78-7 (sodium) 119141-88-7 (free base) 161973-10-0 (magnesium) 217087-09-7 (magnesium hydrate) 161796-84-5 (potassium) 914613-86-8 (strontium) 934714-36-0 (strontium hydrate)
Synonym
Esomeprazole Sodium; S-Omeprazole sodium; (S)-Omeprazole sodium; (–)-Omeprazole sodium
IUPAC/Chemical Name
sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
InChi Key
RYXPMWYHEBGTRV-JIDHJSLPSA-N
InChi Code
InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1/t24-;/m0./s1
SMILES Code
O=[S@](C1=NC2=CC(OC)=CC=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 119141-88-7(Esomeprazole ) 161796-78-7(Esomeprazole Sodium) 934714-36-0(Esomeprazole Strontium) 217087-09-7(Esomeprazole Magnesium Trihydrate)
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor.
In vitro activity:
This study found that the expression of both DDAH and iNOS were significantly downregulated by esomeprazole (Fig. 1). For example, the gene expression of iNOS was increased by about 100-fold upon induction with bleomycin, and treatment with esomeprazole decreased the induction in iNOS expression by about 25-fold (Fig. 1). Reference: J Inflamm (Lond). 2021; 18: 17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136131/
In vivo activity:
The administration of esomeprazole in different doses significantly reduced the MDA levels in the HE+WIR group (P=0.0001<0.001) and the LE+WIR group (P=0.0001<0.001) (Figure 4A; Table 3). Compared with the NS group, the level of GSH in the WIR group was declined (P=0.012<0.05), which was rescued by the high-dose esomeprazole treatment (P=0.036<0.05) (Figure 4B; Table 3). The assessment revealed that the WIR treatment significantly reduced the levels of SOD relative to that of the NS group (P=0.025<0.05), and this condition was reversed by the prophylactic administration of the high-dose esomeprazole (P=0.048<0.05) (Figure 4C; Table 3). The rats in the HE group did not show any significant changes in the levels of MDA (P=0.963), GSH (P=0.980), SOD (P=0.875) and SOD1 (P=0.809) in the stomach tissue compared with the NS group rats (Figure 4A–D). Reference: Drug Des Devel Ther. 2019; 13: 2969–2984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709796/
Solvent mg/mL mM
Solubility
Ethanol 74.0 201.42
Water 74.0 201.42
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 367.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076. 3. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 4. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297.
In vitro protocol:
1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076.
In vivo protocol:
1. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 2. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297.
1: Kumar P, Ganure AL, Subudhi BB, Shukla S. Preparation and characterization of pH-sensitive methyl methacrylate-g-starch/hydroxypropylated starch hydrogels: in vitro and in vivo study on release of esomeprazole magnesium. Drug Deliv Transl Res. 2015 Jun;5(3):243-56. doi: 10.1007/s13346-015-0221-7. PubMed PMID: 25787732. 2: Belal F, Sharaf El-Din M, Tolba MM, Alaa H. Enhanced spectrofluorimetric determination of esomeprazole and pantoprazole in dosage forms and spiked human plasma using organized media. Luminescence. 2015 May;30(3):343-51. doi: 10.1002/bio.2737. Epub 2014 Jul 24. PubMed PMID: 25060291. 3: Xiao YL, Nie YQ, Hou XH, Xie PY, Fang JY, Yuan YZ, Zhou LY, Zhao NQ, Chen MH. The efficacy, safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD: A multicenter, randomized, open-label study in China. J Dig Dis. 2013 Sep;14(9):463-8. doi: 10.1111/1751-2980.12069. PubMed PMID: 23659834. 4: Benetti C, Flammini L, Vivo V, Colombo P, Colombo G, Elviri L, Scarpignato C, Buttini F, Bettini R, Barocelli E, Rossi A. Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. J Control Release. 2016 Oct 10;239:203-10. doi: 10.1016/j.jconrel.2016.08.032. Epub 2016 Aug 26. PubMed PMID: 27574989. 5: Videla R, Sommardahl CS, Elliott SB, Vasili A, Andrews FM. Effects of intravenously administered esomeprazole sodium on gastric juice pH in adult female horses. J Vet Intern Med. 2011 May-Jun;25(3):558-62. doi: 10.1111/j.1939-1676.2011.0716.x. Epub 2011 Apr 1. PubMed PMID: 21457324. 6: Estevez P, Flor S, Boscolo O, Tripodi V, Lucangioli S. Development and validation of a capillary electrophoresis method for determination of enantiomeric purity and related substances of esomeprazole in raw material and pellets. Electrophoresis. 2014 Mar;35(6):804-10. doi: 10.1002/elps.201300334. Epub 2014 Jan 13. PubMed PMID: 24258683. 7: Cui LH, Li C, Wang XH, Yan ZH, He X, Gong SD. The therapeutic effect of high-dose esomeprazole on stress ulcer bleeding in trauma patients. Chin J Traumatol. 2015;18(1):41-3. PubMed PMID: 26169094. 8: Sandström M, Davidson G, Tolia V, Sullivan JE, Långström G, Lundborg P, Brown K. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38. doi: 10.1016/j.clinthera.2012.06.028. Epub 2012 Jul 24. PubMed PMID: 22832034. 9: Pradhan R, Tran TH, Kim SY, Woo KB, Choi YJ, Choi HG, Yong CS, Kim JO. Preparation and characterization of fast dissolving flurbiprofen and esomeprazole solid dispersion using spray drying technique. Int J Pharm. 2016 Apr 11;502(1-2):38-46. doi: 10.1016/j.ijpharm.2016.02.020. Epub 2016 Feb 17. PubMed PMID: 26899979. 10: Bayerdörffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez Muñoz JE, Grundling H, Persson T, Svedberg LE, Keeling N, Eklund S. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016 Apr 14;16:48. doi: 10.1186/s12876-016-0448-x. PubMed PMID: 27080034; PubMed Central PMCID: PMC4831110. 11: Mei J, Yu Y, Ma J, Yu X. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms: a meta-analysis. Pharmazie. 2016 May;71(5):285-91. Review. PubMed PMID: 27348974. 12: Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacother. 2008 Sep;42(9):1247-51. doi: 10.1345/aph.1L079. Epub 2008 Jul 9. PubMed PMID: 18614750. 13: Bai Y, Chen DF, Wang RQ, Chen YX, Shi RH, Tian DA, Chen H, Eklund S, Li ZS; Chinese Peptic Ulcer Bleeding Research Group. Intravenous Esomeprazole for Prevention of Peptic Ulcer Rebleeding: A Randomized Trial in Chinese Patients. Adv Ther. 2015 Nov;32(11):1160-76. doi: 10.1007/s12325-015-0265-6. Epub 2015 Nov 18. PubMed PMID: 26581750. 14: Liu LP, Wang Y, Si R, Yuan M, Cheng K, Guo WY. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Expert Opin Pharmacother. 2016;17(1):7-16. doi: 10.1517/14656566.2016.1110145. Epub 2015 Nov 7. PubMed PMID: 26549402. 15: Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015 Dec;71(12):1461-5. doi: 10.1007/s00228-015-1912-1. Epub 2015 Sep 24. PubMed PMID: 26400679.